Description
Ruxolitinib is a potent Janus-associated Kinase (JAK1 IC50 2.7nM, JAK2 IC50 4.5nM) inhibitor. JAK1 and JAK2 transduce cytokine-mediated signals and are involved in interferon-gamma signaling. Ruxolitinib is reported to block IL-6 signaling and inhibits the proliferation of erythroid progenitors. It is currently being researched as a potential treatment for COVID-19